Satellos Bioscience Inc.
MSLE
$6.38
$0.304.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -31.67% | -20.54% | -4.98% | -34.12% | -38.21% |
| Total Depreciation and Amortization | -71.43% | -73.33% | 73.33% | 55.84% | 118.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -23.37% | -11.83% | -63.80% | 149.89% | 51.79% |
| Change in Net Operating Assets | 86.46% | -96.28% | -295.63% | -363.91% | -1,316.02% |
| Cash from Operations | -28.45% | -29.28% | -44.73% | -41.20% | -51.79% |
| Capital Expenditure | -233.33% | -50.00% | -27.66% | 75.41% | 79.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -809.09% | -301.95% | -2,292.42% | 202.10% | 142.31% |
| Cash from Investing | -809.61% | -302.26% | -2,307.66% | 201.97% | 142.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 61.42% | -92.69% | 1,035.60% | 1,087.51% | -12.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -32.77% | -- | 316.63% | 344.76% | -55.37% |
| Cash from Financing | 44.08% | -94.04% | 15,170.99% | 2,110.84% | 4.77% |
| Foreign Exchange rate Adjustments | 188.65% | 185.84% | 83.54% | 178.27% | 51.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -160.84% | -229.40% | 112.42% | 206.49% | 211.22% |